Imatinib mesylate for the treatment of pulmonary arterial hypertension

甲磺酸伊马替尼 医学 血小板源性生长因子受体 伊马替尼 酪氨酸激酶抑制剂 肺动脉高压 酪氨酸激酶 癌症研究 药理学 临床试验 内科学 髓系白血病 受体 生长因子 癌症
作者
Henrik ten Freyhaus,Daniel Dumitrescu,Eva Maria Berghausen,Marius Vantler,Evren Caglayan,Stephan Rosenkranz
出处
期刊:Expert Opinion on Investigational Drugs [Taylor & Francis]
卷期号:21 (1): 119-134 被引量:65
标识
DOI:10.1517/13543784.2012.632408
摘要

INTRODUCTION: Despite recent advances, pulmonary arterial hypertension (PAH) remains a devastating disease which harbors a poor prognosis. Novel therapeutic approaches directly targeting pulmonary vascular remodeling are warranted. AREAS COVERED: This review delineates the current limitations in the management of PAH and focuses on a novel, anti-proliferative therapeutic concept. It will help readers understand the mechanisms of receptor tyrosine kinase signaling, with a special focus on platelet-derived growth factor (PDGF) receptors and their role in the pathobiology of PAH. Furthermore, it provides a comprehensive summary regarding the rationale, efficacy and safety of the tyrosine kinase inhibitor imatinib mesylate , which potently inhibits the PDGF receptor, as an additional treatment option in PAH. EXPERT OPINION: PDGF is a potent mitogen for pulmonary vascular smooth muscle cells and represents an important mediator of pulmonary vascular remodeling. Imatinib mesylate, a compound that inhibits the Bcr-Abl kinase and was developed for the treatment of chronic myeloid leukemia, also targets PDGF receptors. Both experimental and clinical data indicate that it reverses the vascular remodeling process even when it is fully established. Results from Phase II and III clinical trials suggest potent and prolonged efficacy in patients with severe PAH (i.e., pulmonary vascular resistance > 800 dynes*s*cm(-5)). Future studies should evaluate the long-term clinical efficacy and safety of imatinib, including patients with less impaired hemodynamics. Based on the current knowledge, this compound is likely to become an additional treatment option for patients with PAH and has the potential to at least partially correct the pathology of the disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海的应助被星辞采纳,获得10
刚刚
Yuan88发布了新的文献求助10
刚刚
1秒前
1秒前
2秒前
Mmmin完成签到,获得积分10
2秒前
丘比特的应助被flash采纳,获得10
3秒前
Yuan88发布了新的文献求助10
3秒前
3秒前
6秒前
半岛完成签到 ,获得积分10
6秒前
迷人雪一完成签到,获得积分10
6秒前
6秒前
悟生菌完成签到,获得积分10
7秒前
7秒前
Orange的应助被drizzle采纳,获得10
8秒前
Chris学长完成签到,获得积分10
9秒前
9秒前
9秒前
Yuan88发布了新的文献求助10
9秒前
Rn发布了新的文献求助10
10秒前
11秒前
11秒前
核平铀善完成签到,获得积分10
12秒前
369ninja发布了新的文献求助10
12秒前
ding的应助被公爵采纳,获得10
13秒前
14秒前
14秒前
15秒前
15秒前
caimeng发布了新的文献求助10
16秒前
hsn发布了新的文献求助20
16秒前
星辞完成签到,获得积分10
16秒前
16秒前
二甲双胍发布了新的文献求助10
17秒前
17秒前
wooo完成签到 ,获得积分10
17秒前
平平无奇历飞雨完成签到,获得积分10
18秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784